FDA extends review of Praxis drug for rare epilepsy to December 2026 Jun 29, 2026 04:30PM
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies Jun 29, 2026 04:30PM
FDA grants breakthrough therapy status to Praxis drug for rare epilepsy Jun 22, 2026 08:01AM
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Jun 22, 2026 08:00AM
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference Jun 4, 2026 04:01PM
View Older Stories

Jun 2, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 1, 2026 04:15PM Praxis pauses vormatrigine study after trial misses primary endpoint
Jun 1, 2026 04:15PM Praxis Precision Medicines Provides Vormatrigine Program Update
May 7, 2026 08:00AM Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 5, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 04:01PM Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Apr 14, 2026 07:30AM Praxis Precision Medicines receives FDA acceptance for essential tremor drug
Apr 14, 2026 07:30AM Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Apr 13, 2026 08:01AM Praxis to present ulixacaltamide essential tremor data at AAN 2026
Apr 13, 2026 08:00AM Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Apr 6, 2026 08:00AM Praxis Precision Medicines reports positive trial results for epilepsy drug
Apr 6, 2026 08:00AM Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Apr 2, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30, 2026 04:01PM FDA accepts Praxis PRAX application for epilepsy drug relutrigine
Mar 30, 2026 04:01PM Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Mar 4, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 19, 2026 07:30AM Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Feb 9, 2026 04:01PM Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Feb 4, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2026 04:30PM Praxis Precision Medicines hires epilepsy expert Dr. Orrin Devinsky as head of clinical strategy
Jan 13, 2026 04:30PM Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Jan 12, 2026 08:04AM Praxis plans two drug applications by mid-February, raises $1.5 billion
Jan 12, 2026 08:00AM Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Jan 9, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 8, 2026 04:45PM Praxis appoints two board directors and promotes two executives
Jan 8, 2026 04:45PM Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Dec 29, 2025 08:01AM FDA grants breakthrough therapy designation to Praxis drug for essential tremor
Dec 29, 2025 08:00AM Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Dec 11, 2025 08:02AM Praxis plans to file NDA for relutrigine in rare epilepsies by early 2026
Dec 11, 2025 08:00AM Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Dec 9, 2025 04:01PM Praxis gets FDA agreement to simplify elsunersen trial design
Dec 9, 2025 04:01PM Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Dec 8, 2025 08:00AM Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Dec 4, 2025 04:12PM Praxis stops EMBOLD study early after relutrigine shows efficacy
Dec 4, 2025 04:10PM Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Dec 4, 2025 04:01PM Praxis receives FDA alignment on ulixacaltamide NDA submission plans
Dec 4, 2025 04:01PM Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Dec 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2025 04:01PM Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Nov 20, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Nov 6, 2025 08:00AM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Nov 5, 2025 08:00AM Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Nov 4, 2025 08:00AM Praxis plans early 2026 NDA filing for relutrigine after FDA alignment
Nov 4, 2025 08:00AM Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Oct 16, 2025 07:01AM Praxis reports positive phase 3 results for essential tremor drug
Oct 16, 2025 07:00AM Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Oct 2, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 4, 2025 04:01PM Praxis Precision Medicines to Participate in September Investor Conferences
Sep 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View Older Stories